Stage II Colon Cancer

ASSESS PATIENT’S IMMUNITY TO FIGHT CANCER

How can Immunoscore® help the management of stage II T4N0 patients?

- Identifies with Immunoscore® a greater prognosis value than traditional measurements
- Refines patients’ risk profile
- Helps to spare patients from unnecessary chemotherapy
- Adjusts treatment decision and improves colon cancer patients’ management

Maria, 72-year-old

- T4N0M0
- Moderately differentiated
- MSS Tumor
  - She is clinically at a higher risk

Considered as a candidate for chemotherapy

“Immunoscore® is the most powerful prognostic parameter for identifying patients with good survival”

Maria has an Immunoscore High

Her immune system is present in the tumor to fight cancer

T4N0 patients with an Immunoscore High have a good prognosis and might be spared from chemotherapy.
**CLINICAL UTILITY**

**Prognostic Value of Immunoscore® in stage II T4N0**

Validated on the international SITC study among Stage II T4N0 untreated patients (n=132), Immunoscore® assesses the risk of relapse in Stage II T4N0 colon cancer patients. Patients with an Immunoscore High have Time To Recurrence Rate similar to low risk patients (89%).

![Graph showing the comparison between IS Low and IS High patients](image)

Galon J, Hermitte F, Mlecnik B, et al., J Clin Oncol. 2020; 38.15 (suppl; abstr 4105)

**2 out of 3 T4N0 Patients have a good clinical outcome and might be spared from chemotherapy**

**IMMUNOSCORE® WORKFLOW**

1. **Patient post resection surgery**
2. **Tumor block or unstained slides**
3. **Stain & Scan Slides**
4. **Compute Immunoscore®**
5. **Report Immunoscore® results**

Pathology lab > HalioDx lab

10 days

**CONTACT & FOLLOW US**

HalioDx - Luminy Biotech Entreprises
163 Avenue de Luminy - 13009 Marseille - FRANCE
Phone: +33 (0) 4 91 29 30 90 - Fax: +33 (0) 4 91 29 30 99
Email: infos@haliodx.com

immunoscore-colon.com